Twist Bioscience (TWST): Q3 Revenue Jumps 23% As FY2026 Guidance Raised
Twist Bioscience (TWST) reported Q3 2026 revenue of $118.4M, up 23% YoY, with raised FY2026 guidance to $456M-$457M. Gross margin improved to 52.8%, but net loss was $35.1M. The company completed a $300M public offering and expects adjusted EBITDA breakeven in Q4 2026.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise improve the company's growth narrative, while the capital raise provides runway for expansion.
Market read
Earnings beat and guidance raise are likely to drive short-term buying interest in TWST.
What to watch
Potential dilution from the $300M offering and reliance on continued customer growth.
Background
Twist Bioscience is a publicly traded biotech firm specializing in DNA synthesis and related services.
Ticker impact
Twist Bioscience reported Q3 2026 results with record revenue, raised FY2026 guidance and priced a $300M public offering.
Potential short-term price rally as investors price in higher revenue outlook and fresh capital.
Revenue up 23% YoY, guidance lifted 5%+, and a $300M raise indicate improved fundamentals and liquidity.
Market effects
Positive signal for biotech DNA synthesis and NGS service providers.
U.S. biotech sector may see modest lift.
Limited to biotech investors; no broad market effect.
Counterpoint
The raised guidance may already be priced in; execution risk on breakeven EBITDA could temper upside.
Key entities
- companyTwist Bioscience Corporation
Biotech firm reporting Q3 2026 results and a $300M public offering.
